Bayer Schering Pharma's plan to build a 100 million-euro R&D centre in Beijing marks the company's first major foray into China and is intended as a base camp for further expansion in the fast-growing Asian market.
China has been a hot location for pharmaceutical companies for some years, initially as a location for pharmaceutical production but increasingly for clinical and other R&D functions as well.
For Bayer Schering, China is the third country it has chosen to site an R&D hub in - after existing sites in Germany (at Berlin and Wuppertal) and in the USA (Berkeley). Merck, Lilly and Johnson & Johnson are among other big pharma companies that have gone down the route of globalising their R&D.
More
No comments:
Post a Comment